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Bronchioloalveolar carcinoma of the lung (BAC)appears to be increasing in incidence, with up to a 3-
fold increase reported between 1955 and 1992.1-3 The
cause of this increase is undefined. Proportionately
more patients are women and nonsmokers than with
other forms of lung cancer.4-6 Patients with BAC are
often regarded as having a better prognosis than patients
with similar stage non–small cell lung cancer (NSCLC),
particularly adenocarcinoma.4,7-9 We have previously
evaluated patients with advanced stage disease, con-
trasting clinical findings and outcomes in those patients
with BAC to those with other forms of NSCLC. Patients
with advanced stage BAC were more likely to have
bilateral and multilobar lung parenchymal involvement,
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with subsequent progression predominantly within the
lung parenchyma, and increased survival compared
with patients with other forms of NSCLC.4
Previous reports of patients with resected stage I lung
cancer have shown that such patients with BAC live
longer than patients with other types of NSCLC.8,9
However, there are limited data in the literature regard-
ing the role of limited versus more extensive resections
in patients with stage I BAC. There is even less infor-
mation on the pattern of recurrent disease and how this
is influenced by the surgical approach. We aim to add
information on patient characteristics, the pattern of
disease at presentation and recurrence, and survival
outcomes in patients with stage I BAC and contrast
these findings against those in patients with a similar
stage of adenocarcinoma.
Methods
Background and patient population.  The patients report-
ed in this study were identified in a prior study that developed
a molecular pathologic substaging system in patients with
stage I NSCLC.7 Three hundred seventeen patients under-
went resection for stage I NSCLC at the Brigham and
Women’s Hospital from January 1, 1984, through December
31, 1992. The patients had preoperative stage I disease and
were without evidence of systemic metastasis before surgery
or in the immediate postoperative interval. All patients under-
went mediastinoscopy and/or surgical sampling of hilar and
mediastinal nodes. Seventy-three patients were excluded
from the analysis; 39 patients had 2 or more primary cancers,
5 had surgery at another hospital and the nodal status could
not be verified, 2 patients died within 30 days of the opera-
tion, and no follow-up information could be obtained for 27
patients. The Karnofsky performance status was 90% or
greater in all patients. All patients included lived a minimum
of 60 days after resection. The median periods of follow-up
for patients with BAC and those with adenocarcinoma were
6.2 years and 5.9 years, respectively.
Of the remaining 244 eligible patients, 33 had a diagnosis
of BAC, and 105 had a diagnosis of adenocarcinoma other
than BAC. These patients were selected for this study, which
aimed to further characterize the nature of BAC and to con-
trast the clinical features against those of patients with ade-
nocarcinoma other than BAC. The medical records of all
patients were reviewed for clinical characteristics including
age, sex, cigarette smoking history, site of tumor, type of
resection (limited resection, lobectomy, combination [lobec-
tomy with limited resection], or pneumonectomy). Patient
follow-up was acquired by retrospective chart review and
with the assistance of the Brigham and Women’s Hospital
Tumor Registry. A median follow-up of 6 years was obtained
in both groups, which included the time and location of any
recurrent disease. The study was approved by the Dana
Farber/Partners Cancer Care Investigational Review Board.
Pathology. The pathologic material was reviewed by 2
pathologists. The diagnosis of BAC was made according to
the former description of a peripheral tumor manifesting the
growth of well-differentiated cuboidal or columnar tumor
cells along intact alveolar walls and no evidence of a prima-
ry adenocarcinoma at some extrapulmonary site.10,11 The
specimens were consistent with the new classification by the
World Health Organization (WHO), which describes BAC as
a form of adenocarcinoma with a pure bronchioloalveolar
growth pattern and no evidence of stromal, vascular, or pleur-
al invasion.12 Stage I NSCLC was pathologically confirmed
in all patients; all resected hilar and mediastinal nodes were
proved uninvolved with cancer. Patients were divided into 2
groups: those with BAC and those with adenocarcinoma
other than BAC for the purpose of comparison.
Statistical methods. Comparisons of the groups defined
by histology on the basis of clinical and demographic vari-
ables that are categoric are made by use of a Fisher exact test.
Table I.  Patient characteristics
BAC Adenocarcinoma
No. % No. %
Patients 33 100 105 100
Age (y)
Median 66 — 66 —
Range 42-84 — 39-83 —
Sex
Male 13 39 56 53
Female 20 61 49 47
Smoking history
Nonsmokers 11 33 9 9
Active smokers 15 46 58 55
Ex-smokers 6 18 26 25
Unknown 1 3 12 11
Adenocarcinoma, Adenocarcinoma other than BAC.
Table II. Sites of initial progressive disease
BAC Adenocarcinoma
(n = 12) (n = 39)
No. % No. %
Intrathoracic recurrences
Intrathoracic only 11 92 24 62
Lung 9 75 25 64
Pleural effusion 1 8 4 10
Pericardial effusion 1 8 0 0
Extrathoracic recurrences
Extrathoracic only 1 8 12 31
Bone 0 0 7 18
Brain 0 0 5 13
Adenopathy (C; S/C) 0 0 4 10
Liver 0 0 2 5
Adrenal 0 0 1 3
Adenopathy (axilla) 1 8 0 0
Adenocarcinoma, Adenocarcinoma other than BAC; C, cervical; S/C, supra-
clavicular.
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For disease-free survival (DFS), time was measured from the
operation until recurrence or death. Patients who were alive
and disease free at the most recent follow-up were censored
for this analysis. Survival comparisons reported are from a
log rank test, and estimates of survival were made by the
method of Kaplan and Meier, with the time measured from
the date of the initial operation until death or most recent fol-
low-up (censored).13
Results
Patient characteristics. A total of 138 patients with
stage I NSCLC were eligible for this analysis. Thirty-
three patients had a diagnosis of BAC, and 105
patients had adenocarcinoma (acinar, n = 54; papillary,
n = 14; solid tumor with mucin, n = 25; mixed, n = 9;
poorly differentiated, n = 3).12 The patient characteris-
tics are outlined in Table I. The median age at initial
presentation was similar both in patients with BAC
and in those with adenocarcinoma. There were more
women (61%) than men (39%) within the BAC cohort
as compared with near equal numbers within the
patients with adenocarcinoma (P = .23). Eleven of the
33 patients (33%) with BAC had never smoked as
compared with 9 patients (9%) in the adenocarcinoma
group (P = .0036). Nine (45%) of the 20 women with
BAC were never smokers compared with 2 (15%) of
the 13 men. The median cigarette smoking exposure,
expressed in pack years, in patients with BAC and ade-
nocarcinoma was 30 (range 7-100 years) and 45 (range
10-160 years), respectively. The upper lobes were the
most common site of the primary tumor in both
patients with BAC (n = 21; 64%) and those with ade-
nocarcinoma (n = 70; 67%), with a slight preference
for the right side. Sixty-three percent of patients with
BAC had T1 N0 lesions compared with 52% of
patients with adenocarcinoma.
Surgical interventions. Nineteen patients (58%)
with BAC had lobectomies compared with 72 patients
(69%) with adenocarcinoma. Of the 13 (39%) patients
with BAC who had limited resections, all but 1 had
wedge resections. One patient (3%) with BAC had a
combined lobectomy and wedge resection. Eighteen
patients (17%) with adenocarcinoma had wedge resec-
tions, and 4 (4%) had segmentectomies. Six patients
(6%) with adenocarcinoma had combined lobectomy
and limited resection, and an additional 5 patients (4%)
had pneumonectomies.
Recurrence patterns. Twelve of the 33 patients
(36%) with BAC had recurrent disease compared with
39 of the 105 patients (37%) with adenocarcinoma.
These results are summarized in Table II. The 5-year
DFS in patients with BAC and those with adenocarci-
noma was 74% and 65%, respectively (P = .6). There
was no significant difference in DFS in patients with
BAC resected by lobectomy versus limited resection
(5-year DFS: 83% vs 66%, respectively; P = .38).
However, patients with adenocarcinoma resected by
lobectomy had a statistically significantly longer DFS
than those patients treated by limited resection (5-year
DFS: 76% vs 31%; P = .004).
The recurrences within the patients with resected
BAC (92%) occurred predominantly within the thorax
compared with patients with adenocarcinoma (74%) 
(P = .14). Nine of the 12 recurrences in those patients
with BAC were within the lung parenchyma. Malignant
pleural effusion (n = 1) and pericardial effusions (n =
1) accounted for the sites of recurrence in 2 patients
with BAC. One patient with BAC developed a metasta-
sis in an axillary node. In contrast, extrathoracic metas-
tases were common in the patients (19 of 39 patients,
49%) with adenocarcinoma. Of these patients with
recurrent adenocarcinoma, 18% had metastases to bone
(n = 7), 13% to brain (n = 5), 10% to cervical lymph
nodes (n = 4), 5% to liver (n = 2), and 3% to the adre-
nal glands (n = 1). These findings are summarized in
Tables II and III.
Table III. Comparison of sites of pulmonary recurrences in patients with BAC and those with adenocarcinoma
after either limited resection or lobectomy
BAC Adenocarcinoma
Site of recurrence Limited resection (n = 13) Lobectomy (n = 19) Limited resection (n = 22) Lobectomy (n = 72)
Ipsilateral lung 4* (31%) 2 (11%) 2* (9%), 5† (23%) 4† (6%)
Contralateral lung 0 (0%) 3 (16%) 2 (9%) 9 (12%)
Bilateral lung 1 (8%) 0 (0%) 1 (5%) 0 (0%)
Effusions
Pleural 0 (0%) 1* (5%) 2* (9%) 1* (1%)
Pericardial 1 (8%) 0 (0%) 0 (0%) 0 (0%)
Adenocarcinoma, Adenocarcinoma other than BAC.
*Recurrence in ipsilateral primary lobe.
†Recurrence in ipsilateral nonprimary lobe.
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Survival. The median survivals for patients with
BAC and those with adenocarcinoma were 7 and 6.7
years, respectively. Patients with BAC lived longer (5-
year survival 83%) than patients with adenocarcinoma
(5-year survival 63%) after resection of their stage I
disease (P = .04) (Fig 1). Men with BAC had a greater
median survival than women (7.5 years vs 6.3 years; 
P = .04) as did patients with BAC who never smoked
compared with cigarette smokers (7.8 years vs 6.3
years; P = .04). There was no statistical difference in
survival between patients with BAC treated with either
wedge resection (n = 12) or lobectomy (n = 18) (P =
.24) or between patients with T1 or T2 lesions (P = .9).
Patients with adenocarcinoma had a statistically signif-
icant difference in survival in favor of lobectomies (n =
70; 74% 5-year survival) over limited resections (n =
22; 43% 5-year survival) (P = .02). 
Discussion
The original descriptions of BAC report on patients
with advanced bilateral pulmonary tumors.10,14
Retrospective series of patients report that 35% to
39% of patients with BAC present with stage I dis-
ease15,16 compared with 20% of patients with
NSCLC.17 Currently, BAC is pathologically classi-
fied as a form of adenocarcinoma,12 although BAC
has numerous distinguishing clinical features.
Patients with advanced stage BAC show a specific
tendency for intrapulmonary spread, with limited
regional nodal involvement, and a reduced tendency
for extrathoracic metastases, particularly to brain and
liver.4,18,19 Patients with advanced stage (IIIB and IV)
BAC are moderately responsive to chemotherapy,
with response rates of 20% to 32%4,18,20,21 and have a
1-year survival that is significantly better than that
Table IV. Comparison of patients with stage I BAC reported in the surgical literature
Author Stage I BAC (n) Recurrent disease Median survival (y) Five-year survival (%)
Dumont et al25 71 Not specified — 65
Fujimoto et al21 25 Not specified 6.1 —
Greco et al26 65 Not specified — 75
Harpole et al16 80 34%,* 24%† — 55
Heikkila27 28 Not specified — 57
Regnard et al32 33 Not specified — 56
Williams et al8 67 Not specified — 81
Present study 33 35%,* 38%† 7.0 83
*Recurrent disease after lobectomy.
†Recurrent disease after limited pulmonary resection.
Fig 1. Postoperative survival in patients with pathologic stage I BAC compared with patients with stage I adeno-
carcinoma other than BAC (5-year survival: 83% vs 63%, respectively; P = .04). Circular marks represent censored
data (, BAC; , adenocarcinoma).
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for patients with similar stage adenocarcinoma and
other forms of NSCLC.4
Nineteen studies have reported on 1383 patients with
various stages of BAC who have received surgical
resections for curative or palliative intent.* Of these, 13
studies reported data on 709 patients with stage I
BAC.† The majority of these retrospective studies did
not include a comparison group, and the pathology
specimens were not reviewed again to confirm the
diagnosis as was performed in our study. They focus
predominantly on symptoms, pathologic features of
BAC, and radiologic features as prognostic factors.
However, there are limited data on the recurrence rates
and sites of recurrent disease in patients with early
stage BAC. This study adds information about the sites
of disease at initial presentation, the patterns of surgi-
cal resection and subsequent recurrent disease, and sur-
vival of patients with stage I BAC and adenocarcinoma.
The majority of the 13 studies that include data on
stage I BAC do not break down the patient character-
istics per stage of disease. Three studies, including
greater than 70% of patients with stage I BAC, report
that 58%,9 61%,34 and 86%25 of patients were male.
This finding is in contrast to our results, which
revealed a predominance of female patients.
Significantly more patients with stage I BAC in our
series were nonsmokers (33%) compared with
patients with adenocarcinoma (9%). Between 10%
and 32% of patients with BAC in the surgical litera-
ture are nonsmokers.3,19,29 The smoking status was
unknown in 25% of the patients in the study that
reported the rate of cigarette smoking of 10%.29
The sites of disease at presentation in patients with
BAC have been reported in 2 previous studies.24,29
Neither study specifies the number of patients with stage
I disease, although they state that 56%24 and 73%29 had
solitary nodules. Both studies report that these solitary
nodules were most commonly found in the upper lobes
(46% and 63%, respectively). Our data similarly show
involvement of the upper lobes being the most common
site of disease at presentation, both in patients with BAC
(63%) and in those with adenocarcinoma (66%).
Lobectomy is the most commonly performed surgical
procedure in patients undergoing resection for BAC, with
between 56%28 to 87%25 of patients treated in this man-
ner. Retrospective series including greater than 70% of
patients with stage I BAC report that limited resections
are performed on 3%25 to 18% of the patients.19 Fifty-
eight percent of our patients with BAC had a lobectomy,
and the majority of the remainder (39%) had a limited
resection. Lobectomy was also more commonly per-
formed in our patients with adenocarcinoma than limited
resection (69% vs 21%, respectively).
Two studies compare recurrence rates after resection
in patients with BAC and those with adenocarcino-
ma.9,27 Grover and Piantadosi9 reported a recurrence
rate of 0.0723 and 0.12 per patient-year of exposure in
patients with stage T1 N0 M0 BAC (n = 150) and ade-
nocarcinoma (n = 504), respectively (P = .007). The
second study included 33 patients with stage I to stage
III BAC, of whom 28 patients (85%) had stage I dis-
ease.27 However, only 59% of their patients with ade-
nocarcinoma had stage I disease, making comparisons
between the clinical characteristics of the patients with
BAC and those with adenocarcinoma more difficult.
The authors reported that 39% of patients with BAC
had either ipsilateral or contralateral intrapulmonary
metastases compared with 13% of patients with adeno-
carcinoma (P < .025). Twenty-nine percent of patients
with BAC and 69% of the patients with adenocarcino-
ma had distant metastases, respectively (P = .001). Our
data compare patients of similar stage BAC and adeno-
carcinoma and demonstrate the greater tendency for
intrapulmonary metastases to develop, with limited
extrathoracic recurrences in patients with BAC.
One other study, from Harpole and associates,16
reports on recurrences after surgical resection in
patients with stage I BAC. No comparison group was
included. They compared recurrences in patients with
stage I BAC after lobectomy (n = 63) and wedge
resection (n = 17) and reported a greater recurrence
after lobectomy than after wedge resection (34% vs
24% at 3 years). Their data conflict with the results of
our study, which show a greater DFS in patients with
BAC resected by lobectomy.
Eight studies report on median and 5-year overall sur-
vival in patients with stage I BAC.* The reported 5-year
survivals range from 54% to 81%. One of these studies
compared their patients with BAC to those with stage I
adenocarcinoma (81% vs 65%, respectively). These find-
ings are nearly identical to those reported in our series.
These data support the belief that patients with BAC have
a better prognosis than patients with adenocarcinoma.
The survival of our patients with adenocarcinoma is com-
parable to that recently reported by Fry and coworkers.17
Grover and Piantadosi9 add additional support of a
greater survival in patients with BAC in a study reporting
mortality rates in patients with T1 N0 M0 NSCLC.
Patients with T1 N0 M0 BAC and similar stage adeno-
carcinoma had mortality rates of 0.0737 and 0.10 per
*References 3,8,9,14,16,19,21-33.
†References 8,9,16,19,21,22,25-29,32,33. *References 8,9,16,21,25,26,28,32.
patient-year of exposure, respectively (P = .0542). The
results are summarized in Table IV.
In conclusion, this study confirms that patients
with BAC exhibit a different clinical pattern to
patients with adenocarcinoma. Although the DFS of
patients with resected stage I BAC or adenocarcino-
ma is similar, patients with stage I BAC are nearly 4-
fold less prone to the development of extrathoracic
disease. Patients with stage I BAC had a longer over-
all survival than patients with similar stage adenocar-
cinoma and represent a more favorable prognostic
group. Further research is required to define the eti-
ology, clinical course, and molecular abnormalities in
patients with BAC to generate more appropriate ther-
apeutic interventions.
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